|Classification and external resources|
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium). The most common area affected is the lining of the lungs and chest wall. Less commonly the lining of the abdomen and rarely the sac surrounding the heart, or the sac surrounding the testis may be affected. Signs and symptoms of mesothelioma may include shortness of breath due to fluid around the lung, a swollen abdomen, chest wall pain, cough, feeling tired, and weight loss. These symptoms typically come on slowly.
Greater than 80% of mesothelioma is caused by exposure to asbestos. The greater the exposure the greater the risk. As of 2013 about 125 million people have been exposed to asbestos at work. High rates of disease occur in people who mine asbestos, produce products from asbestos, work with asbestos products, live with asbestos workers, or work in buildings containing asbestos. Often it takes around 40 years for the disease to begin. Washing the clothing of someone who worked with asbestos also increases the risk. Other risk factors include genetics and infection with the simian virus 40. The diagnosis may be suspected based on chest X-ray and CT scan findings, and is confirmed by either examining fluid produced by the cancer or by a tissue biopsy of the cancer.
Prevention centers around reducing exposure to asbestos. Treatment often includes surgery, radiation therapy, and chemotherapy. A procedure known as pleurodesis, which involves using substances such as talc to scar together the pleura, may be used to prevent more fluid from building up around the lungs. Chemotherapy often includes the medications cisplatin and pemetrexed. The percentage of people that survive five years following diagnosis is on average 8% in the United States.
In 2013 about 50,000 people had mesothelioma and 34,000 died from the disease. Rates of mesothelioma vary in different areas of the world. Rates are higher in Australia and Great Britain and lower in Japan. It occurs in about 3,000 people per year in the United States. It occurs more often in males than females. Rates of disease have increased since the 1950s. Diagnosis typically occurs after the age of 65 and most deaths occur around 70 years old. The disease was rare before the commercial use of asbestos.
- 1 Signs and symptoms
- 2 Cause
- 3 Pathophysiology
- 4 Diagnosis
- 5 Prevention
- 6 Screening
- 7 Treatment
- 8 Prognosis
- 9 Epidemiology
- 10 History
- 11 Society and culture
- 12 Research
- 13 References
- 14 External links
Signs and symptoms
Symptoms or signs of mesothelioma may not appear until 20 to 50 years (or more) after exposure to asbestos. Shortness of breath, cough, and pain in the chest due to an accumulation of fluid in the pleural space (pleural effusion) are often symptoms of pleural mesothelioma.
The most common symptoms of peritoneal mesothelioma are abdominal swelling and pain due to ascites (a buildup of fluid in the abdominal cavity). Other features may include weight loss, fever, night sweats, poor appetite, vomiting, constipation, and umbilical hernia. If the cancer has spread beyond the mesothelium to other parts of the body, symptoms may include pain, trouble swallowing, or swelling of the neck or face.
These symptoms may be caused by mesothelioma or by other, less serious conditions.
Mesothelioma that affects the pleura can cause these signs and symptoms:
- Chest wall pain
- Pleural effusion, or fluid surrounding the lung
- Shortness of breath
- Fatigue or anemia
- Wheezing, hoarseness, or a cough
- Blood in the sputum (fluid) coughed up (hemoptysis)
In severe cases, the person may have many tumor masses. The individual may develop a pneumothorax, or collapse of the lung. The disease may metastasize, or spread to other parts of the body.
Tumors that affect the abdominal cavity often do not cause symptoms until they are at a late stage. Symptoms include:
- Abdominal pain
- Ascites, or an abnormal buildup of fluid in the abdomen
- A mass in the abdomen
- Problems with bowel function
- Weight loss
In severe cases of the disease, the following signs and symptoms may be present:
- Blood clots in the veins, which may cause thrombophlebitis
- Disseminated intravascular coagulation, a disorder causing severe bleeding in many body organs
- Jaundice, or yellowing of the eyes and skin
- Low blood sugar level
- Pleural effusion
- Pulmonary emboli, or blood clots in the arteries of the lungs
- Severe ascites
A mesothelioma does not usually spread to the bone, brain, or adrenal glands. Pleural tumors are usually found only on one side of the lungs.
Pericardial mesothelioma is not well characterized, but observed cases have included cardiac symptoms, specifically constrictive pericarditis, heart failure, pulmonary embolism, and cardiac tamponade. They have also included nonspecific symptoms, including substernal chest pain, orthopnea (shortness of breath when lying flat), and cough. These symptoms are caused by the tumor encasing or infiltrating the heart.
Working with asbestos is the most common risk factor for mesothelioma. In the United States, asbestos is considered the major cause of malignant mesothelioma and has been considered "indisputably" associated with the development of mesothelioma. Indeed, the relationship between asbestos and mesothelioma is so strong that many consider mesothelioma a “signal” or “sentinel” tumor. A history of asbestos exposure exists in most cases. However, mesothelioma has been reported in some individuals without any known exposure to asbestos. In rare cases, mesothelioma has also been associated with irradiation of the chest or abdomen, intrapleural thorium dioxide (thorotrast) as a contrast medium, and inhalation of other fibrous silicates, such as erionite or talc. Some studies suggest that simian virus 40 (SV40) may act as a cofactor in the development of mesothelioma. This has been confirmed in animal studies, but studies in humans are inconclusive. Pericardial mesothelioma may not be associated with asbestos exposure.
Asbestos was known in antiquity, but it was not mined and widely used commercially until the late 19th century. Its use greatly increased during World War II. Since the early 1940s, millions of American workers have been exposed to asbestos dust. Initially, the risks associated with asbestos exposure were not publicly known. However, an increased risk of developing mesothelioma was later found among naval personnel (e.g., Navy, Marine Corps, and Coast Guard), shipyard workers, people who work in asbestos mines and mills, producers of asbestos products, workers in the heating and construction industries, and other tradespeople. Today, the official position of the U.S. Occupational Safety and Health Administration (OSHA) and the U.S. EPA is that protections and "permissible exposure limits" required by U.S. regulations, while adequate to prevent most asbestos-related non-malignant disease, are not adequate to prevent or protect against asbestos-related cancers such as mesothelioma. Likewise, the British Government's Health and Safety Executive (HSE) states formally that any threshold for exposure to asbestos must be at a very low level and it is widely agreed that if any such threshold does exist at all, then it cannot currently be quantified. For practical purposes, therefore, HSE assumes that no such "safe" threshold exists. Others have noted as well that there is no evidence of a threshold level below which there is no risk of mesothelioma. There appears to be a linear, dose-response relationship, with increasing dose producing increasing disease. Nevertheless, mesothelioma may be related to brief, low level or indirect exposures to asbestos. The dose necessary for effect appears to be lower for asbestos-induced mesothelioma than for pulmonary asbestosis or lung cancer. Again, there is no known safe level of exposure to asbestos as it relates to increased risk of mesothelioma.
The duration of exposure to asbestos causing mesothelioma can be short. For example, cases of mesothelioma have been documented with only 1–3 months of exposure. People who work with asbestos wear personal protective equipment to lower their risk of exposure.
Latency, the time from first exposure to manifestation of disease, is prolonged in the case of mesothelioma. It is virtually never less than fifteen years and peaks at 30–40 years. In a review of occupationally related mesothelioma cases, the median latency was 32 years. Based upon the data from Peto et al., the risk of mesothelioma appears to increase to the third or fourth power from first exposure.
The incidence of mesothelioma has been found to be higher in populations living near naturally occurring asbestos. People can be exposed to naturally occurring asbestos in areas where mining or road construction is occurring, or when the asbestos-containing rock is naturally weathered. Another common route of exposure is through asbestos-containing soil, which is used to whitewash, plaster, and roof houses in Greece. In central Cappadocia, Turkey, mesothelioma was causing 50% of all deaths in three small villages—Tuzköy, Karain, and Sarıhıdır. Initially, this was attributed to erionite. Environmental exposure to asbestos has caused mesothelioma in places other than Turkey, including Corsica, Greece, Cyprus, China, and California. In Metsovo, this exposure had resulted in mesothelioma incidence around 300 times more than expected in asbestos free populations and was associated with very frequent pleural calcification known as "Metsovo Lung".
The documented presence of asbestos fibers in water supplies and food products has fostered concerns about the possible impact of long-term and, as yet, unknown exposure of the general population to these fibers.
Exposure to talc is also a risk factor for mesothelioma; exposure can affect those who live near talc mines, work in talc mines, or work in talc mills.
Exposure to asbestos fibers has been recognized as an occupational health hazard since the early 20th century. Numerous epidemiological studies have associated occupational exposure to asbestos with the development of pleural plaques, diffuse pleural thickening, asbestosis, carcinoma of the lung and larynx, gastrointestinal tumors, and diffuse malignant mesothelioma of the pleura and peritoneum. Asbestos has been widely used in many industrial products, including cement, brake linings, gaskets, roof shingles, flooring products, textiles, and insulation.
Commercial asbestos mining at Wittenoom, Western Australia, took place from 1937 to 1966. The first case of mesothelioma in the town occurred in 1960. The second case was in 1969, and new cases began to appear more frequently thereafter. The lag time between initial exposure to asbestos and the development of mesothelioma varied from 12 years 9 months up to 58 years. A cohort study of miners employed at the mine reported that 85 deaths attributable to mesothelioma had occurred by 1985. By 1994, 539 reported deaths due to mesothelioma had been reported in Western Australia.
Occupational exposure to asbestos in the United States mainly occurs when people are maintaining buildings that already have asbestos. Approximately 1.3 million US workers are exposed to asbestos annually; in 2002, an estimated 44,000 miners were potentially exposed to asbestos.
Paraoccupational secondary exposure
Family members and others living with asbestos workers have an increased risk of developing mesothelioma, and possibly other asbestos-related diseases. This risk may be the result of exposure to asbestos dust brought home on the clothing and hair of asbestos workers via washing a worker's clothes or coming into contact with asbestos-contaminated work clothing. To reduce the chance of exposing family members to asbestos fibres, asbestos workers are usually required to shower and change their clothing before leaving the workplace.
Asbestos in buildings
Many building materials used in both public and domestic premises prior to the banning of asbestos may contain asbestos. Those performing renovation works or DIY activities may expose themselves to asbestos dust. In the UK use of Chrysotile asbestos was banned at the end of 1999. Brown and blue asbestos was banned in the UK around 1985. Buildings built or renovated prior to these dates may contain asbestos materials.
In a recent research carried on white American population in 2012, it was found that people with a germline mutation in their BAP1 gene are at higher risk of developing mesothelioma and uveal melanoma.
Erionite is a zeolite mineral with similar properties to asbestos and is known to cause mesothelioma. Detailed epidemiological investigation has shown that erionite causes mesothelioma mostly in families with a genetic predisposition. Erionite is found in deposits in the Western United States, where it is used in gravel for road surfacing, and in Turkey, where it is used to construct homes. In Turkey, the United States, and Mexico, erionite has been associated with mesothelioma and has thus been designated a "known human carcinogen" by the US National Toxicology Program.
The mesothelium consists of a single layer of flattened to cuboidal cells forming the epithelial lining of the serous cavities of the body including the peritoneal, pericardial and pleural cavities. Deposition of asbestos fibers in the parenchyma of the lung may result in the penetration of the visceral pleura from where the fiber can then be carried to the pleural surface, thus leading to the development of malignant mesothelial plaques. The processes leading to the development of peritoneal mesothelioma remain unresolved, although it has been proposed that asbestos fibers from the lung are transported to the abdomen and associated organs via the lymphatic system. Additionally, asbestos fibers may be deposited in the gut after ingestion of sputum contaminated with asbestos fibers.
Pleural contamination with asbestos or other mineral fibers has been shown to cause cancer. Long thin asbestos fibers (blue asbestos, amphibole fibers) are more potent carcinogens than "feathery fibers" (chrysotile or white asbestos fibers). However, there is now evidence that smaller particles may be more dangerous than the larger fibers. They remain suspended in the air where they can be inhaled, and may penetrate more easily and deeper into the lungs. "We probably will find out a lot more about the health aspects of asbestos from [the World Trade Center attack], unfortunately," said Dr. Alan Fein, chief of pulmonary and critical-care medicine at North Shore-Long Island Jewish Health System.
Mesothelioma development in rats has been demonstrated following intra-pleural inoculation of phosphorylated chrysotile fibers. It has been suggested that in humans, transport of fibers to the pleura is critical to the pathogenesis of mesothelioma. This is supported by the observed recruitment of significant numbers of macrophages and other cells of the immune system to localized lesions of accumulated asbestos fibers in the pleural and peritoneal cavities of rats. These lesions continued to attract and accumulate macrophages as the disease progressed, and cellular changes within the lesion culminated in a morphologically malignant tumor.
Experimental evidence suggests that asbestos acts as a complete carcinogen with the development of mesothelioma occurring in sequential stages of initiation and promotion. The molecular mechanisms underlying the malignant transformation of normal mesothelial cells by asbestos fibers remain unclear despite the demonstration of its oncogenic capabilities (see next-but-one paragraph). However, complete in vitro transformation of normal human mesothelial cells to malignant phenotype following exposure to asbestos fibers has not yet been achieved. In general, asbestos fibers are thought to act through direct physical interactions with the cells of the mesothelium in conjunction with indirect effects following interaction with inflammatory cells such as macrophages.
Analysis of the interactions between asbestos fibers and DNA has shown that phagocytosed fibers are able to make contact with chromosomes, often adhering to the chromatin fibers or becoming entangled within the chromosome. This contact between the asbestos fiber and the chromosomes or structural proteins of the spindle apparatus can induce complex abnormalities. The most common abnormality is monosomy of chromosome 22. Other frequent abnormalities include structural rearrangement of 1p, 3p, 9p and 6q chromosome arms.
Asbestos has also been shown to mediate the entry of foreign DNA into target cells. Incorporation of this foreign DNA may lead to mutations and oncogenesis by several possible mechanisms:
- Inactivation of tumor suppressor genes
- Activation of oncogenes
- Activation of proto-oncogenes due to incorporation of foreign DNA containing a promoter region
- Activation of DNA repair enzymes, which may be prone to error
- Activation of telomerase
- Prevention of apoptosis
Several genes are commonly mutated in mesothelioma, and may be prognostic factors. These include epidermal growth factor receptor (EGFR) and C-Met, receptor tyrosine kinasesoverexpressed in many mesotheliomas. Some association has been found with EGFR and epithelioid histology but no clear association has been found between EGFR overexpression and overall survival. Expression of AXL receptor tyrosine kinase is a negative prognostic factor. Expression of PDGFRB is a positive prognostic factor. In general, mesothelioma is characterized by loss of function in tumor suppressor genes, rather than by an overexpression or gain of function in oncogenes.
Asbestos fibers have been shown to alter the function and secretory properties of macrophages, ultimately creating conditions which favour the development of mesothelioma. Following asbestos phagocytosis, macrophages generate increased amounts of hydroxyl radicals, which are normal by-products of cellular anaerobic metabolism. However, these free radicals are also known clastogenic and membrane-active agents thought to promote asbestos carcinogenicity. These oxidants can participate in the oncogenic process by directly and indirectly interacting with DNA, modifying membrane-associated cellular events, including oncogene activation and perturbation of cellular antioxidant defences.
Asbestos also may possess immunosuppressive properties. For example, chrysotile fibres have been shown to depress the in vitro proliferation of phytohemagglutinin-stimulated peripheral blood lymphocytes, suppress natural killer cell lysis and significantly reduce lymphokine-activated killer cell viability and recovery. Furthermore, genetic alterations in asbestos-activated macrophages may result in the release of potent mesothelial cell mitogens such as platelet-derived growth factor (PDGF) and transforming growth factor-β (TGF-β) which in turn, may induce the chronic stimulation and proliferation of mesothelial cells after injury by asbestos fibres.
As an environmentally triggered malignancy, mesothelioma tumors have been found to be polyclonal in origin by performing a X-inactivation based assay on epitheloid and biphasic tumors obtained from female patients. These results suggest that an environmental factor, e.g. asbestos exposure, may damage and transform a group of cells in the tissue, therefore result in a population of tumor cells that are, albeit slightly, genetically different.
Diagnosis of mesothelioma can be suspected with imaging but is confirmed with biopsy. It must be clinically and histologically differentiated from other pleural and pulmonary malignancies, including reactive pleural disease, primary lung carcinoma, pleural metastases of other cancers, and other primary pleural cancers. Primary pericardial mesothelioma is often diagnosed after it has metastasized to lymph nodes or the lungs.
Diagnosing mesothelioma is often difficult because the symptoms are similar to those of a number of other conditions. Diagnosis begins with a review of the patient's medical history. A history of exposure to asbestos may increase clinical suspicion for mesothelioma. A physical examination is performed, followed by chest X-ray and often lung function tests. The X-ray may reveal pleural thickening commonly seen after asbestos exposure and increases suspicion of mesothelioma. A CT (or CAT) scan or an MRI is usually performed. If a large amount of fluid is present, abnormal cells may be detected by cytopathology if this fluid is aspirated with a syringe. For pleural fluid, this is done by thoracentesis or tube thoracostomy (chest tube); for ascites, with paracentesis or ascitic drain; and for pericardial effusion with pericardiocentesis. While absence of malignant cells on cytology does not completely exclude mesothelioma, it makes it much more unlikely, especially if an alternative diagnosis can be made (e.g. tuberculosis, heart failure). However, with primary pericardial mesothelioma, pericardial fluid may not contain malignant cells and a tissue biopsy is more useful in diagnosis. Using conventional cytology diagnosis of malignant mesothelioma is difficult, but immunocytochemistry has greatly enhanced the accuracy of cytology.
Generally, a biopsy is needed to confirm a diagnosis of malignant mesothelioma. A doctor removes a sample of tissue for examination under a microscope by a pathologist. A biopsy may be done in different ways, depending on where the abnormal area is located. If the cancer is in the chest, the doctor may perform a thoracoscopy. In this procedure, the doctor makes a small cut through the chest wall and puts a thin, lighted tube called a thoracoscope into the chest between two ribs. Thoracoscopy allows the doctor to look inside the chest and obtain tissue samples. Alternatively, the chest surgeon might directly open the chest (thoracotomy). If the cancer is in the abdomen, the doctor may perform a laparoscopy. To obtain tissue for examination, the doctor makes a small incision in the abdomen and inserts a special instrument into the abdominal cavity. If these procedures do not yield enough tissue, more extensive diagnostic surgery may be necessary.
Immunohistochemical studies play an important role for the pathologist in differentiating malignant mesothelioma from neoplastic mimics, such as breast or lung cancer that has metastasized to the pleura. There are numerous tests and panels available, but no single test is perfect for distinguishing mesothelioma from carcinoma or even benign versus malignant. The positive markers indicate that mesothelioma is present; if other markers are positive it may indicate another type of cancer, such as breast or lung adenocarcinoma. Calretinin is a particularly important marker in distinguishing mesothelioma from metastatic breast or lung cancer.
|EMA (epithelial membrane antigen) in a membranous distribution||CEA (carcinoembryonic antigen)|
|WT1 (Wilms' tumour 1)||B72.3|
|HBME-1 (human mesothelial cell 1)||TTF-1 (thyroid transcription factor-1)|
|Osteopontin||Epithelial cell adhesion molecule (EpCAM)|
|Estrogen receptor alpha|
There are three main histological subtypes of malignant mesothelioma: epithelioid, sarcomatous, and biphasic. Epithelioid and biphasic mesothelioma make up approximately 75-95% of mesotheliomas and have been well characterized histologically, whereas sarcomatous mesothelioma has not been studied extensively. Most mesotheliomas express high levels of cytokeratin 5 regardless of subtype.
Epithelioid mesothelioma is characterized by high levels of calretinin.
Sarcomatous mesothelioma does not express high levels of calretinin.
Other morphological subtypes have been described:
- Clear cell
- Cartilaginous and osseous metaplasia
- Metastatic adenocarcinoma
- Pleural sarcoma
- Synovial sarcoma
- Metastatic clear cell renal cell carcinoma
- Metastatic osteosarcoma
Staging of mesothelioma is based on the recommendation by the International Mesothelioma Interest Group. TNM classification of the primary tumor, lymph node involvement, and distant metastasis is performed. Mesothelioma is staged Ia–IV (one-A to four) based on the TNM status.
Mesothelioma can be prevented in most cases by preventing exposure to asbestos. The US National Institute for Occupational Safety and Health maintains a recommended exposure limit of 0.1 asbestos fiber per cubic centimeter.
There is no universally agreed protocol for screening people who have been exposed to asbestos. Screening tests might diagnose mesothelioma earlier than conventional methods thus improving the survival prospects for patients. The serum osteopontin level might be useful in screening asbestos-exposed people for mesothelioma. The level of soluble mesothelin-related protein is elevated in the serum of about 75% of patients at diagnosis and it has been suggested that it may be useful for screening. Doctors have begun testing the Mesomark assay which measures levels of soluble mesothelin-related proteins (SMRPs) released by diseased mesothelioma cells.
Mesothelioma is generally resistant to radiation and chemotherapy treatment. Long-term survival and cures are exceedingly rare. Treatment of malignant mesothelioma at earlier stages has a better prognosis. Clinical behavior of the malignancy is affected by several factors including the continuous mesothelial surface of the pleural cavity which favors local metastasis via exfoliated cells, invasion to underlying tissue and other organs within the pleural cavity, and the extremely long latency period between asbestos exposure and development of the disease. The histological subtype and the patient's age and health status also help predict prognosis. The epithelioid histology responds better to treatment and has a survival advantage over sarcomatoid histology.
Surgery, by itself, has proved disappointing. In one large series, the median survival with surgery (including extrapleural pneumonectomy) was only 11.7 months. However, research indicates varied success when used in combination with radiation and chemotherapy (Duke, 2008), or with one of the latter. A pleurectomy/decortication is the most common surgery, in which the lining of the chest is removed. Less common is an extrapleural pneumonectomy (EPP), in which the lung, lining of the inside of the chest, the hemi-diaphragm and the pericardium are removed. In localized pericardial mesothelioma, pericardectomy can be curative; when the tumor has metastasized, pericardectomy is a palliative care option. The entire tumor is not often able to be removed.
For patients with localized disease, and who can tolerate a radical surgery, radiation can be given post-operatively as a consolidative treatment. The entire hemithorax is treated with radiation therapy, often given simultaneously with chemotherapy. Delivering radiation and chemotherapy after a radical surgery have led to extended life expectancy in selected patient populations. It can also induce severe side-effects, including fatal pneumonitis. As part of a curative approach to mesothelioma, radiotherapy is commonly applied to the sites of chest drain insertion, in order to prevent growth of the tumor along the track in the chest wall.
Although mesothelioma is generally resistant to curative treatment with radiotherapy alone, palliative treatment regimens are sometimes used to relieve symptoms arising from tumor growth, such as obstruction of a major blood vessel. Radiation therapy, when given alone with curative intent, has never been shown to improve survival from mesothelioma. The necessary radiation dose to treat mesothelioma that has not been surgically removed would be very toxic. Radiotherapy is of some use in pericardial mesothelioma.
Chemotherapy is the only treatment for mesothelioma that has been proven to improve survival in randomised and controlled trials. The landmark study published in 2003 by Vogelzang and colleagues compared cisplatin chemotherapy alone with a combination of cisplatin and pemetrexed (brand name Alimta) chemotherapy in patients who had not received chemotherapy for malignant pleural mesothelioma previously and were not candidates for more aggressive "curative" surgery. This trial was the first to report a survival advantage from chemotherapy in malignant pleural mesothelioma, showing a statistically significant improvement in median survival from 10 months in the patients treated with cisplatin alone to 13.3 months in the group of patients treated with cisplatin in the combination with pemetrexed and who also received supplementation with folate and vitamin B12. Vitamin supplementation was given to most patients in the trial and pemetrexed related side effects were significantly less in patients receiving pemetrexed when they also received daily oral folate 500mcg and intramuscular vitamin B12 1000mcg every 9 weeks compared with patients receiving pemetrexed without vitamin supplementation. The objective response rate increased from 20% in the cisplatin group to 46% in the combination pemetrexed group. Some side effects such as nausea and vomiting, stomatitis, and diarrhoea were more common in the combination pemetrexed group but only affected a minority of patients and overall the combination of pemetrexed and cisplatin was well tolerated when patients received vitamin supplementation; both quality of life and lung function tests improved in the combination pemetrexed group. In February 2004, the United States Food and Drug Administration approved pemetrexed for treatment of malignant pleural mesothelioma. However, there are still unanswered questions about the optimal use of chemotherapy, including when to start treatment, and the optimal number of cycles to give. Cisplatin and pemetrexed together give patients a median survival of 12.1 months.
Cisplatin in combination with raltitrexed has shown an improvement in survival similar to that reported for pemetrexed in combination with cisplatin, but raltitrexed is no longer commercially available for this indication. For patients unable to tolerate pemetrexed, cisplatin in combination with gemcitabine or vinorelbine is an alternative, or vinorelbine on its own, although a survival benefit has not been shown for these drugs. For patients in whom cisplatin cannot be used, carboplatin can be substituted but non-randomised data have shown lower response rates and high rates of haematological toxicity for carboplatin-based combinations, albeit with similar survival figures to patients receiving cisplatin.
In January 2009, the United States FDA approved using conventional therapies such as surgery in combination with radiation and or chemotherapy on stage I or II Mesothelioma after research conducted by a nationwide study by Duke University concluded an almost 50 point increase in remission rates.
In pericardial mesothelioma, chemotherapy - typically adriamycin and/or cisplatin - is primarily used to shrink the tumor and is not curative.
Treatment regimens involving immunotherapy have yielded variable results. For example, intrapleural inoculation of Bacillus Calmette-Guérin (BCG) in an attempt to boost the immune response, was found to be of no benefit to the patient (while it may benefit patients with bladder cancer). Mesothelioma cells proved susceptible to in vitro lysis by LAK cells following activation by interleukin-2 (IL-2), but patients undergoing this particular therapy experienced major side effects. Indeed, this trial was suspended in view of the unacceptably high levels of IL-2 toxicity and the severity of side effects such as fever and cachexia. Nonetheless, other trials involving interferon alpha have proved more encouraging with 20% of patients experiencing a greater than 50% reduction in tumor mass combined with minimal side effects.
Heated intraoperative intraperitoneal chemotherapy
This technique is used in conjunction with surgery, including in patients with malignant pleural mesothelioma. The surgeon removes as much of the tumor as possible followed by the direct administration of a chemotherapy agent, heated to between 40 and 48 °C, in the abdomen. The fluid is perfused for 60 to 120 minutes and then drained. High concentrations of selected drugs are then administered into the abdominal and pelvic surfaces. Heating the chemotherapy treatment increases the penetration of the drugs into tissues. Also, heating itself damages the malignant cells more than the normal cells.
All of the standard approaches to treating solid tumors—radiation, chemotherapy, and surgery—have been investigated in patients with malignant pleural mesothelioma. Although surgery, by itself, is not very effective, surgery combined with adjuvant chemotherapy and radiation (trimodality therapy) has produced significant survival extension (3–14 years) among patients with favorable prognostic factors. However, other large series of examining multimodality treatment have only demonstrated modest improvement in survival (median survival 14.5 months and only 29.6% surviving 2 years). Reducing the bulk of the tumor with cytoreductive surgery is key to extending survival. Two surgeries have been developed: extrapleural pneumonectomy and pleurectomy/decortication. The indications for performing these operations are unique. The choice of operation namely depends on the size of the patient's tumor. This is an important consideration because tumor volume has been identified as a prognostic factor in mesothelioma. Pleurectomy/decortication spares the underlying lung and is performed in patients with early stage disease when the intention is to remove all gross visible tumor (macroscopic complete resection), not simply palliation. Extrapleural pneumonectomy is a more extensive operation that involves resection of the parietal and visceral pleurae, underlying lung, ipsilateral (same side) diaphragm, and ipsilateral pericardium. This operation is indicated for a subset of patients with more advanced tumors, who can tolerate a pneumonectomy.
Mesothelioma has a poor prognosis. The median survival time for pleural mesothelioma is 12 months from diagnosis. Women, young people, people with low-stage cancers, and people with epithelioid cancers have better prognoses. Negative prognostic factors include sarcomatoid or biphasic histology, high platelet counts (above 400,000), age over 50 years, white blood cell counts above 15.5, low glucose levels in the pleural fluid, low albumin levels, and high fibrinogen levels. Several markers are under investigation as prognostic factors, including nuclear grade, and serum c-reactive protein. Long-term survival is rare.
Pericardial mesothelioma has a 10-month median survival time.
In peritoneal mesothelioma, high expression of WT-1 protein indicates a worse prognosis.
Although reported incidence rates have increased in the past 20 years, mesothelioma is still a relatively rare cancer. The incidence rate varies from one country to another, from a low rate of less than 1 per 1,000,000 in Tunisia and Morocco, to the highest rate in Britain, Australia and Belgium: 30 per 1,000,000 per year. For comparison, populations with high levels of smoking can have a lung cancer incidence of over 1,000 per 1,000,000. Incidence of malignant mesothelioma currently ranges from about 7 to 40 per 1,000,000 in industrialized Western nations, depending on the amount of asbestos exposure of the populations during the past several decades. Worldwide incidence is estimated at 1-6 per 1,000,000. Incidence of mesothelioma lags behind that of asbestosis due to the longer time it takes to develop; due to the cessation of asbestos use in developed countries, mesothelioma incidence is expected to decrease. Incidence is expected to continue increasing in developing countries due to continuing use of asbestos. Mesothelioma occurs more often in men than in women and risk increases with age, but this disease can appear in either men or women at any age. Approximately one fifth to one third of all mesotheliomas are peritoneal. Less than 5% of mesotheliomas are pericardial. The prevalence of pericardial mesothelioma is less than 0.002%; it is more common in men than women. It typically occurs in a person's 50s-70s.
Between 1940 and 1979, approximately 27.5 million people were occupationally exposed to asbestos in the United States. Between 1973 and 1984, the incidence of pleural mesothelioma among Caucasian males increased 300%. From 1980 to the late 1990s, the death rate from mesothelioma in the USA increased from 2,000 per year to 3,000, with men four times more likely to acquire it than women. More than 80% of mesotheliomas are caused by asbestos exposure.
The incidence of peritoneal mesothelioma is 0.5–3.0 per million per year in men, and 0.2–2.0 per million per year in women.
Mesothelioma accounts for less than 1% of all cancers diagnosed in the UK, (around 2,600 people were diagnosed with the disease in 2011), and it is the seventeenth most common cause of cancer death (around 2,400 people died in 2012).
The connection between asbestos exposure and mesothelioma was discovered in the 1970s. In the United States, asbestos manufacture stopped in 2002. Asbestos exposure thus shifted from workers in asbestos textile mills, friction product manufacturing, cement pipe fabrication, and insulation manufacture and installation to maintenance workers in asbestos-containing buildings.
Society and culture
Mesothelioma, though rare, has had a number of notable patients:
- Bernie Banton, an Australian workers' rights activist, fought a long battle for compensation from James Hardie after he contracted mesothelioma after working for that company. He claimed James Hardie knew of the dangers of asbestos before he began work with the substance making insulation for power stations. Mesothelioma eventually took his life along with his brothers' and hundreds of James Hardie workers'. James Hardie made an undisclosed settlement with Banton only when his mesothelioma had reached its final stages and he was expected to have no more than 48 hours to live. Australian Prime Minister Kevin Rudd mentioned Banton's extended struggle in his acceptance speech after winning the 2007 Australian federal election.
- Steve McQueen, American actor, was diagnosed with peritoneal mesothelioma on December 22, 1979. He was not offered surgery or chemotherapy because doctors felt the cancer was too advanced. McQueen subsequently sought alternative treatments at clinics in Mexico. He died of a heart attack on November 7, 1980, in Juárez, Mexico, following cancer surgery. He may have been exposed to asbestos while serving with the U.S. Marines as a young adult—asbestos was then commonly used to insulate ships' piping—or from its use as an insulating material in automobile racing suits (McQueen was an avid racing driver and fan).
- Cynthia Stelljes, oboist and founding member of the Canadian classical quartet Quartetto Gelato, died from the disease on December 29, 2006.
- Bill Tait, the husband of early anti-asbestos campaigner Nancy Tait, died of the condition in 1968, sparking his wife's subsequent activism.
- Bruce Vento, U.S. Congressman, died of mesothelioma in 2000. The Bruce Vento Hopebuilder award is given yearly by his wife at the MARF Symposium to persons or organizations who have done the most to support mesothelioma research and advocacy.
- Warren Zevon, an American rock singer-songwriter, was diagnosed with inoperable peritoneal mesothelioma in 2002. Zevon refused treatments due to concerns that they would serve to only incapacitate him, and instead opted to record his final album. He died on September 7, 2003, at the age of 56, in his Los Angeles home. His album, The Wind, was nominated for several Grammy awards, winning two.
Although life expectancy with this disease is typically limited, there are notable survivors. In July 1982, Stephen Jay Gould, a well-regarded paleontologist, was diagnosed with peritoneal mesothelioma. After his diagnosis, Gould wrote "The Median Isn't the Message", in which he argued that statistics such as median survival are useful abstractions, not destiny. Gould lived for another 20 years, eventually succumbing to cancer not linked to his mesothelioma.
Some people who were exposed to asbestos have collected damages for an asbestos-related disease, including mesothelioma. Compensation via asbestos funds or class action lawsuits is an important issue in law practices regarding mesothelioma.
The first lawsuits against asbestos manufacturers were in 1929. Since then, many lawsuits have been filed against asbestos manufacturers and employers, for neglecting to implement safety measures after the links between asbestos, asbestosis, and mesothelioma became known (some reports seem to place this as early as 1898). The liability resulting from the sheer number of lawsuits and people affected has reached billions of dollars. The amounts and method of allocating compensation have been the source of many court cases, reaching up to the United States Supreme Court, and government attempts at resolution of existing and future cases. However, to date, the US Congress has not stepped in and there are no federal laws governing asbestos compensation. In 2013, the "Furthering Asbestos Claim Transparency (FACT) Act of 2013" passed the US House of representatives and was sent to the US Senate, where it was referred to the Senate Judiciary Committee. As the Senate did not vote on it before the end of the 113th Congress, it died in committee. It was revived in the 114th Congress, where it has not yet been brought before the House for a vote.
The first lawsuit against asbestos manufacturers was brought in 1929. The parties settled that lawsuit, and as part of the agreement, the attorneys agreed not to pursue further cases. In 1960, an article published by Wagner et al. was seminal in establishing mesothelioma as a disease arising from exposure to asbestos. The article referred to over 30 case studies of people who had suffered from mesothelioma in South Africa. Some exposures were transient and some were mine workers. Prior to the use of advanced microscopy techniques, malignant mesothelioma was often diagnosed as a variant form of lung cancer. In 1962 McNulty reported the first diagnosed case of malignant mesothelioma in an Australian asbestos worker. The worker had worked in the mill at the asbestos mine in Wittenoom from 1948 to 1950.
In the town of Wittenoom, asbestos-containing mine waste was used to cover schoolyards and playgrounds. In 1965 an article in the British Journal of Industrial Medicine established that people who lived in the neighbourhoods of asbestos factories and mines, but did not work in them, had contracted mesothelioma.
Despite proof that the dust associated with asbestos mining and milling causes asbestos-related disease, mining began at Wittenoom in 1943 and continued until 1966. In 1974 the first public warnings of the dangers of blue asbestos were published in a cover story called "Is this Killer in Your Home?" in Australia's Bulletin magazine. In 1978 the Western Australian Government decided to phase out the town of Wittenoom, following the publication of a Health Dept. booklet, "The Health Hazard at Wittenoom", containing the results of air sampling and an appraisal of worldwide medical information.
By 1979 the first writs for negligence related to Wittenoom were issued against CSR and its subsidiary ABA, and the Asbestos Diseases Society was formed to represent the Wittenoom victims.
In Leeds, England the Armley asbestos disaster involved several court cases against Turner & Newall where local residents who contracted mesothelioma claimed compensation because of the asbestos pollution from the company's factory. One notable case was that of June Hancock, who contracted the disease in 1993 and died in 1997.
The WT-1 protein is overexpressed in mesothelioma and is being researched as a potential target for drugs.
- "Malignant Mesothelioma—Patient Version". NCI. Retrieved 3 April 2016.
- "Malignant Mesothelioma Treatment–Patient Version (PDQ®)". NCI. September 4, 2015. Retrieved 3 April 2016.
- Robinson, BM (November 2012). "Malignant pleural mesothelioma: an epidemiological perspective.". Annals of cardiothoracic surgery 1 (4): 491–6. PMID 23977542.
- Sardar, MR; Kuntz, C; Patel, T; Saeed, W; Gnall, E; Imaizumi, S; Lande, L (2012). "Primary pericardial mesothelioma unique case and literature review.". Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital 39 (2): 261–4. PMID 22740748.
- Panou, V; Vyberg, M; Weinreich, UM; Meristoudis, C; Falkmer, UG; Røe, OD (June 2015). "The established and future biomarkers of malignant pleural mesothelioma.". Cancer treatment reviews 41 (6): 486–95. PMID 25979846.
- Kondola, S; Manners, D; Nowak, AK (12 February 2016). "Malignant pleural mesothelioma: an update on diagnosis and treatment options.". Therapeutic advances in respiratory disease. PMID 26873306.
- Gulati, M; Redlich, CA (March 2015). "Asbestosis and environmental causes of usual interstitial pneumonia.". Current opinion in pulmonary medicine 21 (2): 193–200. PMID 25621562.
- Whittemore, Alice S. (2006). Cancer epidemiology and prevention (3rd ed.). Oxford: Oxford University Press. p. 669. ISBN 9780199747979.
- "Malignant Mesothelioma Treatment–Patient Version (PDQ®)". NCI. September 4, 2015. Retrieved 3 April 2016.
- "Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent) By Primary Cancer Site, Sex and Time Period" (pdf). NCI. Retrieved 3 April 2016.
- Global Burden of Disease Study 2013, Collaborators (22 August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet (London, England) 386 (9995): 743–800. PMID 26063472.
- GBD 2013 Mortality and Causes of Death, Collaborators (10 January 2015). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet (London, England) 385 (9963): 117–71. PMID 25530442.
- "What are the key statistics about malignant mesothelioma?". American Cancer Society. 2016-02-17. Retrieved 3 April 2016.
- Barreiro, TJ; Katzman, PJ (2006). "Malignant mesothelioma: a case presentation and review". The Journal of the American Osteopathic Association 106 (12): 699–704. PMID 17242414.
- Raza, A; Huang, WC; Takabe, K (2014). "Advances in the management of peritoneal mesothelioma". World Journal of Gastroenterology 20 (33): 11700–11712. doi:10.3748/wjg.v20.i33.11700. PMC 4155360. PMID 25206274.
- EBSCO database verified by URAC; accessed from Mount Sinai Hospital, New York
- Kanarek, Marty S., Phd., MPH, Annals of Epidemiology Volume 21, Issue 9 , Pages 688-697, September 2011
- Roggli VL, Sharma A, Butnor KJ, Sporn T, Vollmer RT (2002). "Malignant mesothelioma and occupational exposure to asbestos: a clinicopathological correlation of 1445 cases". Ultrastruct Pathol 26 (2): 55–65. doi:10.1080/01913120252959227. PMID 12036093.
- Sporn TA, Roggli VL (2004). "Mesothelioma". In Roggli VL, Oury TD, Sporn TA. Pathology of Asbestos-associated Diseases (2nd ed.). Springer. p. 104.
- Gennaro V, Finkelstein MM, Ceppi M, et al. (March 2000). "Mesothelioma and lung tumors attributable to asbestos among petroleum workers". Am. J. Ind. Med. 37 (3): 275–82. doi:10.1002/(SICI)1097-0274(200003)37:3<275::AID-AJIM5>3.0.CO;2-I. PMID 10642417.
- Selikoff IJ (1986). "Occupational Respiratory Diseases". Public Health and Preventative Medicine (12th ed.). Appleton-Century-Crofts. p. 532.
- Henderson DW, et al. (2004). "After Helsinki: A multidisciplinary review of the relationship between asbestos exposure and lung cancer, with emphasis on studies published during 1997–2004". Pathology 36 (6): 517–550. doi:10.1080/00313020400010955. PMID 15841689.
- "CDC - NIOSH Publications and Products - Current Intelligence Bulletin 62: Asbestos Fibers and Other Elongate Meneral Particles: State of the Science and Roadmap for Research". www.cdc.gov. Retrieved 2015-08-25.
- Broaddus VC, Robinson BW (2010). "Chapter 75". Murray & Nadel's Textbook of Respiratory Medicine (5th ed.). Saunders Elsevier. ISBN 978-1-4160-4710-0.
- Holland-Frei (2010). "Chapter 79". Cancer Medicine (8th ed.). People's Medical Publishing House USA. ISBN 978-1607950141.
- Fishman's Pulmonary Diseases and Disorders (4th ed.). McGraw-Hill. 2008. p. 1537. ISBN 0-07-145739-9.
- Maitra, A; Kumar V (2007). Robbins Basic Pathology (8th ed.). Saunders Elsevier. p. 536. ISBN 978-1-4160-2973-1.
- NIOSH Working Group Paper from the Centers for Disease Control, 1980
- Hillerdal G (August 1999). "Mesothelioma: cases associated with non-occupational and low dose exposures". Occup Environ Med 56 (8): 505–13. doi:10.1136/oem.56.8.505. PMC 1757769. PMID 10492646.
- Peto J, Seidman H, Selikoff IJ (January 1982). "Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment". Br. J. Cancer 45 (1): 124–35. doi:10.1038/bjc.1982.15. PMC 2010947. PMID 7059455.
- Burdorf A, Dahhan M, Swuste P (2003). "Occupational characteristics of cases with asbestos-related diseases in The Netherlands". Ann Occup Hyg 47 (6): 485–92. doi:10.1093/annhyg/meg062. PMID 12890657.
- "Hygiene standards for airborne amosite asbestos dust. British Occupational Hygiene Society Committee on Hygiene Standards". Ann Occup Hyg 16 (1): 1–5. 1973. doi:10.1093/annhyg/16.1.1. PMID 4775386.
- Lanphear BP, Buncher CR (July 1992). "Latent period for malignant mesothelioma of occupational origin". J Occup Med 34 (7): 718–21. PMID 1494965.
- Constantopoulos SH. Environmental mesothelioma associated with tremolite asbestos: Lessons from the experiences of Turkey, Greece, Corsica, New Caledonia and Cyprus. Regulatory Toxicology and Pharmacology, 2008; 52: S110-S115
- Weissman, David; Kiefer, Max (22 November 2011). "Erionite: An Emerging North American Hazard". National Institute for Occupational Safety and Health.
- Dogan, Umran (2003). "Mesothelioma in Cappadocian villages". Indoor and Built Environment (Ankara: Sage) 12 (6): 367–375. doi:10.1177/1420326X03039065. ISSN 1420-326X.
- Carbone, Michelle; Emri, Salih; Steele, Ian; Tuncer, Murat; Pass, Harvey I.; Baris, Y. Izzettin; et al. (2007). "A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes". Nature Reviews Cancer 7 (2): 147–54. doi:10.1038/nrc2068. PMID 17251920. Missing
|last3=in Authors list (help)
- "Learn About Asbestos". US Environmental Protection Agency. Retrieved 2016-07-08.
- Berry, G; Reid, A; Aboagye-Sarfo, P (2012). "Malignant mesotheliomas in former miners and millers of crocidolite at Wittenoom (Western Australia) after more than 50 years follow-up". British Journal of Cancer 106 (5): 1016–1020. doi:10.1038/bjc.2012.23. PMC 3305966. PMID 22315054.
- Protecting Workers' Families: A Research Agenda of the Workers' Family Protection Task Force. National Institute for Occupational Safety and Health. DHHS (NIOSH) Publication No. 2002-113.
- Peipins LA, Lewin M, Campolucci S, et al. (November 2003). "Radiographic abnormalities and exposure to asbestos-contaminated vermiculite in the community of Libby, Montana, USA". Environ. Health Perspect. 111 (14): 1753–9. doi:10.1289/ehp.6346. PMC 1241719. PMID 14594627.
- Germline BAP1 mutations predispose to malignant mesothelioma Testa et al. 43(10):1022-5 - Nature Genetics
- "The Junkman's Answer to Terrorism: Use More Asbestos" (PDF). Center for Media and Democracy: Prwatch.org. 2001. Retrieved 2010-08-20.
- Chiosea, S; Krasinskas, A; Cagle, PT; Mitchell, KA; Zander, DS; Dacic, S (June 2008). "Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas.". Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 21 (6): 742–7. PMID 18327208.
- Davidson, Ben (2015-06-01). "Prognostic factors in malignant pleural mesothelioma". Human Pathology 46 (6): 789–804. doi:10.1016/j.humpath.2015.02.006. ISSN 1532-8392. PMID 25824607.
- Reid, Glen (2015-06-01). "MicroRNAs in mesothelioma: from tumour suppressors and biomarkers to therapeutic targets". Journal of Thoracic Disease 7 (6): 1031–1040. doi:10.3978/j.issn.2072-1439.2015.04.56. ISSN 2072-1439. PMC 4466421. PMID 26150916.
- Evaluation of clonal origin of malignant mesothelioma Comertpay et al.- Journal of Translational Medicine 2014, 12:301
- Ceresoli GL, Gridelli C, Santoro A, Santoro A (July 2007). "Multidisciplinary treatment of malignant pleural mesothelioma". Oncologist 12 (7): 850–863. doi:10.1634/theoncologist.12-7-850. PMID 17673616.
- Rusch, VW (October 1995). "A proposed new international TNM staging system for malignant pleural mesothelioma" (PDF). Chest 108 (4): 1122–8. doi:10.1378/chest.108.4.1122. PMID 7555126.
- Robinson BW, Creaney J, Lake R, et al. (July 2005). "Soluble mesothelin-related protein—a blood test for mesothelioma". Lung Cancer 49 (Suppl 1): S109–11. doi:10.1016/j.lungcan.2005.03.020. PMID 15950789.
- Beyer HL, Geschwindt RD, et al. (April 2007). "MESOMARK: a potential test for malignant pleural mesothelioma". Clinical Chemistry 53 (4): 666–672. doi:10.1373/clinchem.2006.079327. PMID 17289801.
- Haber SE, Haber JM (2011). "Malignant mesothelioma: a clinical study of 238 cases". Ind Health 49 (2): 166–72. doi:10.2486/indhealth.MS1147. PMID 21173534.
- Borasio P, Berruti A, Billé A, et al. (February 2008). "Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients". Eur J Cardiothorac Surg 33 (2): 307–13. doi:10.1016/j.ejcts.2007.09.044. PMID 18164622.
- Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma, Allen AM and alt, in Int J Radiat Oncol Biol Phys, 2006 Jul 1;65(3):640-5.
- "Pleural Mesothelioma". Retrieved 20 October 2014.
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. (July 2003). "Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma". J. Clin. Oncol. 21 (14): 2636–44. doi:10.1200/JCO.2003.11.136. PMID 12860938.
- Santoro A, O'Brien ME, Stahel RA, et al. (July 2008). "Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program". J Thorac Oncol 3 (7): 756–63. doi:10.1097/JTO.0b013e31817c73d6. PMID 18594322.
- Sugarbaker PH, Welch LS, Mohamed F, Glehen O (July 2003). "A review of peritoneal mesothelioma at the Washington Cancer Institute". Surg Oncol Clin N Am 12 (3): 605–21, xi. doi:10.1016/S1055-3207(03)00045-0. PMID 14567020.
Online manual: Management of Peritoneal Surface Malignancy.
- Richards WG, Zellos L, Bueno R, et al. (April 2006). "Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma". J. Clin. Oncol. 24 (10): 1561–7. doi:10.1200/JCO.2005.04.6813. PMID 16575008.
- Pass HI, Temeck BK, Kranda K, et al. (1998). "Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma". J Thorac Cardiovasc Surg 115 (2): 310–7; discussion 317–8. doi:10.1016/S0022-5223(98)70274-0. PMID 9475525.
- Sugarbaker, DJ (2006). "Macroscopic complete resection: the goal of primary surgery in multimodality therapy for pleural mesothelioma". J Thorac Oncol 1 (2): 175–176. doi:10.1097/01243894-200602000-00014. PMID 17409850.
- Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. (2004). "Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies". J Thorac Cardiovasc Surg 128 (1): 138–146. doi:10.1016/j.jtcvs.2004.02.021. PMID 15224033.
- Bianchi, C; Bianchi T (June 2007). "Malignant mesothelioma: global incidence and relationship with asbestos". Industrial Health 45 (3): 379–387. doi:10.2486/indhealth.45.379. PMID 17634686.
- Robinson BW, Lake RA (October 2005). "Advances in malignant mesothelioma". The New England Journal of Medicine 353 (15): 1591–603. doi:10.1056/NEJMra050152. PMID 16221782.
- Restrepo, Carlos S.; Vargas, Daniel; Ocazionez, Daniel; Martínez-Jiménez, Santiago; Betancourt Cuellar, Sonia L.; Gutierrez, Fernando R. (2013-10-01). "Primary pericardial tumors". Radiographics: A Review Publication of the Radiological Society of North America, Inc 33 (6): 1613–1630. doi:10.1148/rg.336135512. ISSN 1527-1323. PMID 24108554.
- "DB-397.0.REPORT.JN.ppt" (PDF). Retrieved 2010-08-20.
- Boffetta, P (June 2007). "Epidemiology of peritoneal mesothelioma: a review". Annals of Oncology 18 (6): 985–990. doi:10.1093/annonc/mdl345. PMID 17030547.
- "Mesothelioma statistics". Cancer Research UK. Retrieved 28 October 2014.
- Lerner, Barron H. (2005-11-15). "McQueen's Legacy of Laetrile". New York Times. Retrieved May 12, 2010.
- Gould, Stephen Jay. "The Median Isn't the Message" (PDF). Retrieved May 23, 2013.
- Branley, Alison (7 May 2013). "Survivor sees his illness as a 'gift'". Herald News. Retrieved 7 May 2013.
- ORTIZ V. FIBREBOARD CORP. (97-1704) 527 U.S. 815 (1999) had individual liability from a single corporation and its insurance carriers of nearly $2 billion.
- ORTIZ V. FIBREBOARD CORP. (97-1704) 527 U.S. 815 (1999)
- "H.R.982 - 113th Congress (2013-2014): Furthering Asbestos Claim Transparency (FACT) Act of 2013 - Congress.gov - Library of Congress". Library of Congress. Retrieved 20 October 2014.
- "H.R.526 - 114th Congress (2015-2016): Furthering Asbestos Claim Transparency (FACT) Act of 2015 - Congress.gov - Library of Congress". Library of Congress. Retrieved 1 Dec 2015.
- Wagner JC, Sleggs CA, Marchand P (October 1960). "Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province". Br J Ind Med. 17 (4): 260–71. doi:10.1136/oem.17.4.260. PMC 1038078. PMID 13782506.
- Alastair J Moore, Robert J Parker, John Wiggins (2008). "Malignant mesothelioma". Orphanet Journal of Rare Diseases 3 (34): 1750–1172. doi:10.1186/1750-1172-3-34. PMC 2652430. PMID 19099560.
- McNulty JC (December 1962). "Malignant pleural mesothelioma in an asbestos worker". Med J Aust 49 (2): 953–4. PMID 13932248.
- "June Hancock Research Fund". Retrieved 2010-03-01.
|Wikinews has news related to:|
|Wikibooks has a book on the topic of: Radiation Oncology/Lung/Mesothelioma|